|
EGR2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.97359994592273E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.0517999965719E-08 |
| Normal-vs-Stage2 |
1.39889999584142E-08 |
| Normal-vs-Stage3 |
7.51530004894363E-09 |
| Normal-vs-Stage4 |
2.70860001094775E-09 |
| Stage1-vs-Stage2 |
6.160400E-01 |
| Stage1-vs-Stage3 |
3.818400E-01 |
| Stage1-vs-Stage4 |
1.029360E-01 |
| Stage2-vs-Stage3 |
8.357200E-01 |
| Stage2-vs-Stage4 |
3.550200E-01 |
| Stage3-vs-Stage4 |
4.252000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.18690000050492E-08 |
| Normal-vs-AfricanAmerican |
1.78830000030494E-07 |
| Normal-vs-Asian |
2.33560000229005E-08 |
| Caucasian-vs-AfricanAmerican |
8.435800E-01 |
| Caucasian-vs-Asian |
8.483600E-01 |
| AfricanAmerican-vs-Asian |
9.244000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.12179998623674E-09 |
| Normal-vs-Female |
2.46610000198544E-08 |
| Male-vs-Female |
2.189700E-04 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.70040001260475E-09 |
| Normal-vs-Age(41-60Yrs) |
3.39629999679403E-08 |
| Normal-vs-Age(61-80Yrs) |
3.29799998421976E-09 |
| Normal-vs-Age(81-100Yrs) |
5.63950000032065E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.961600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.974200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.593200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.311370E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.840000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.316600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.15049999999972E-05 |
| Classical-VS-Follicular |
3.718400E-01 |
| Classical-VS-Other |
5.090400E-01 |
| Classical-VS-Normal |
1.17480000172421E-08 |
| Tall-VS-Follicular |
1.812330E-02 |
| Tall-VS-Other |
3.932600E-01 |
| Tall-VS-Normal |
5.2420001672715E-10 |
| Follicular-VS-Other |
1.625850E-01 |
| Follicular-VS-Normal |
3.43540000002918E-07 |
| Other-VS-Normal |
1.11669999913744E-08 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.25839999531863E-08 |
| Normal-vs-N1 |
3.67840002901687E-09 |
| N0-vs-N1 |
2.205400E-01 |
|
|
